ERBB2 and head and neck squamous cell carcinoma: The in vivo antitumor activity of T‐DXd was evaluated in the low HER2 expressing FaDu and UMSCC‐47 xenograft model to ensure that T‐DXd would work on multiple low HER2 expressing HNSCC cell lines.